Pharma - icon
Areas we work for


The landscape is rapidly changing for pharma companies. Against a backdrop of patent expiries and cheap generic imports, they are now faced with lobbying cash-strapped governments to earmark healthcare budgets for new drugs; while having to justify to their shareholders the shape and direction of R&D budgets.

What used to be a conversation between manufacturer and healthcare professional is now a public debate involving politicians, accountants and the media. The relationship between you and each of these groups needs careful management to ensure that your message is properly heard by all relevant parties.